1. Home
  2. SPOK vs ATYR Comparison

SPOK vs ATYR Comparison

Compare SPOK & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spok Holdings Inc.

SPOK

Spok Holdings Inc.

HOLD

Current Price

$11.72

Market Cap

267.8M

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.84

Market Cap

69.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPOK
ATYR
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.8M
69.2M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
SPOK
ATYR
Price
$11.72
$0.84
Analyst Decision
Hold
Hold
Analyst Count
1
8
Target Price
$14.00
$4.20
AVG Volume (30 Days)
189.9K
1.4M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
10.43%
N/A
EPS Growth
2.74
N/A
EPS
0.75
N/A
Revenue
$139,708,000.00
N/A
Revenue This Year
$1.70
$9,628.95
Revenue Next Year
N/A
$156.94
P/E Ratio
$15.97
N/A
Revenue Growth
1.49
N/A
52 Week Low
$11.68
$0.64
52 Week High
$19.31
$7.29

Technical Indicators

Market Signals
Indicator
SPOK
ATYR
Relative Strength Index (RSI) 29.89 43.50
Support Level $11.68 $0.82
Resistance Level $13.72 $0.85
Average True Range (ATR) 0.43 0.07
MACD -0.09 -0.02
Stochastic Oscillator 2.61 7.78

Price Performance

Historical Comparison
SPOK
ATYR

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: